rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KTTA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Coastlands Capital buys $805,944 Pasithea Therapeutics stock
      Nov 18Investing.comKTTA
      Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients
      Nov 13BenzingaKTTA
      Pasithea reports tumor reductions in neurofibromatosis trial
      Nov 13Investing.comKTTA
      Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
      Nov 3Yahoo FinanceKTTA
      Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
      Oct 28Yahoo FinanceKTTAKTTAW
      Pasithea reports prolonged stable disease in PAS-004 cancer trial
      Oct 23Investing.comKTTAKTTAW
      Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
      Oct 23Yahoo FinanceKTTAKTTAW
      Pasithea at Chardan conference: early nf1 data, safety focus
      Oct 20Investing.comKTTAKTTAW
      Pasithea Therapeutics Announces Nasdaq Warrant Expiration

      Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailKTTAKTTAW
      Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

      - Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - The European Neurofibromatosis Conference 2026 will take place in Vienna, Austria, from November 12–14, 2026 MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004,

      Sep 14Yahoo FinanceKTTAKTTAW
      Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

      -- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) -- MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases inc

      Sep 3Yahoo FinanceKTTAKTTAW
      Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance

      Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

      Aug 22The Globe and MailKTTAKTTAW

      This is the newest page. Registered accounts read further back.